Finance

Lists
ENGN:NASDAQ
enGene Therapeutics Inc
US$ १.७०
-१.७३%
(-०.०३०) 1D
अक्टोबर १२, १६:००:०१ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ENGN...
Open
US$ १.७३
High
US$ १.७४
Low
US$ १.६९
Mkt. cap
११.३९ करोड
Avg. vol.
७.२७ लाख
Volume
०.००
52-wk high
US$ १२.२५
52-wk low
US$ १.४०
EPS
-US$ २.०८
Beta
-०.२९
Shares outstanding
६.७० करोड
No. of employees
८२
Open
US$ १.७३
High
US$ १.७४
Low
US$ १.६९
Mkt. cap
११.३९ करोड
Avg. vol.
७.२७ लाख
Volume
०.००
52-wk high
US$ १२.२५
52-wk low
US$ १.४०
EPS
-US$ २.०८
Beta
-०.२९
Shares outstanding
६.७० करोड
No. of employees
८२
News stories
From web sources and news partners
About enGene Therapeutics Inc
CEO-
Employees८२
Founded-
Headquarters-
Sector-
Websiteengene.com
Analyst ratings
Based on 5 analysts giving stock ratings to ENGN in the past 3 months
Hold
Buy
1
Hold
3
Sell
1
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for ENGN in the last 3 months.
Highest
Current US$ १.७०
US$ ४.०० (+१३५.२९%)
Average
US$ २.५० (+४७.०६%)
Lowest
US$ २.०० (+१७.६५%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yanan Zhu
Wells Fargo
Hold
Maintained
US$ २.००
+१७.६%
10/02/2026
David Dai
UBS
Hold
Reiterated
US$ २.००
+१७.६%
09/16/2026
Mani Foroohar
Leerink Partners
Hold
Reiterated
US$ २.००
+१७.६%
09/09/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
US$ ४.००
+१३५.३%
09/09/2026
Judah Frommer
Morgan Stanley
Sell
Maintained
-
-
08/12/2026
Michael Schmidt
Guggenheim
Hold
Maintained
-
-
06/16/2026
Leland Gershell
Oppenheimer
Hold
Maintained
-
-
05/08/2026
Sean McCutcheon
Raymond James
Buy
Maintained
US$ ४.००
+१३५.३%
05/08/2026
Allison Bratzel
Piper Sandler
Hold
Downgraded
US$ ४.००
+१३५.३%
05/08/2026
Silvan Tuerkcan
Citizens JMP
Hold
Downgraded
-
-
05/08/2026
Unknown Analyst
WBB Securities
Buy
Initiated
US$ २१.५०
+१,१६४.७%
04/13/2026
Xin Yang NG‏
USmart Securities
Buy
Initiated
US$ २१.५०
+१,१६४.७%
04/13/2026
Xin Yang NG‏
USmart Securities
Buy
Initiated
US$ २१.५०
+१,१६४.७%
04/13/2026
Kelsey Goodwin
Piper Sandler
Buy
Maintained
-
-
03/26/2026
Maury Raycroft
Jefferies
Buy
Maintained
US$ २८.००
+१,५४७.१%
02/25/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ अक्टोबर
२०२६ जनवरी
२०२६ अप्रिल
२०२६ जुलाई
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
३.१७ करोड
२.२३ करोड
२.२२ करोड
२.०१ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
७७.५९ लाख
८९.३० लाख
९७.७३ लाख
१.३९ करोड
Operating expense
३.९५ करोड
३.१२ करोड
३.२० करोड
३.४० करोड
Total operating expenses
३.९५ करोड
३.१२ करोड
३.२० करोड
३.४० करोड
Operating income
-३.९५ करोड
-३.१२ करोड
-३.२० करोड
-३.४० करोड
Other non operating income
४.४८ लाख
-
-
-
EBT including unusual items
-३.८४ करोड
-२.९८ करोड
-३.०२ करोड
-३.२५ करोड
EBT excluding unusual items
-३.८४ करोड
-२.९३ करोड
-३.०२ करोड
-३.२५ करोड
Income tax expense
-४.९७ लाख
-
-
-
Effective tax rate
१.२९%
-
-
-
Other operating expenses
-
-
-
-
Net income
-३.७९ करोड
-२.९८ करोड
-३.०२ करोड
-३.२५ करोड
Net profit margin
-
-
-
-
Earnings per share
-०.७३
-०.४४
-०.४३
-०.४७
Interest and investment income
१९.७५ लाख
२७.४० लाख
२६.६३ लाख
२४.०१ लाख
Interest expense
-७.५० लाख
-७.३२ लाख
-७.४५ लाख
-८.४३ लाख
Net interest expenses
१२.२५ लाख
२०.०८ लाख
१९.१८ लाख
१५.५८ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-३.९३ करोड
-३.१० करोड
-३.१८ करोड
-३.३८ करोड
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google एपहरू